...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacopsychiatry >Efficacy and tolerability of ziprasidone vsolanzapine in naive first-episode schizophrenia: A 6-week, randomized, open-label, flexible-dose study
【24h】

Efficacy and tolerability of ziprasidone vsolanzapine in naive first-episode schizophrenia: A 6-week, randomized, open-label, flexible-dose study

机译：齐拉西酮vsolanzapine在未治疗的首发精神分裂症中的疗效和耐受性：一项为期6周，随机，开放标签，灵活剂量的研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Although some previous studies have compared the 2 medicines, ziprasidone and olanzapine most selected chronic patients as subjects. Therefore, the present study was designed to compare the efficacy and safety of ziprasidone vs. olanzapine in naive first-episode schizophrenia. Methods: 80 patients were randomly assigned to a 6-week treatment either with 80-160 mg/day of ziprasidone or 10-20 mg/day of olanzapine. The primary efficacy measurements were the Positive and Negative Syndrome Scale and Clinical Global Impression-severity scale scores. The second efficacy measurement was the response rate of treatment. Tolerability assessments were also performed. Results: 79 patients completed the trial. The average dose was 127.5 mg/day with ziprasidone and 19.1 mg/day with olanzapine. No significant differences were found between the 2 groups in primary or secondary efficacy measurements at each visit point (all p>0.05). Body weight significantly increased with olanzapine, and more extrapyramidal symptoms were observed with ziprasidone (all p<0.05). Both medicines were well tolerated, and no serious adverse events were observed. Conclusion: Ziprasidone was as effective as olanzapine in short-term treatment for first-episode schizophrenia, and both medicines were well tolerated.
机译：简介：尽管以前的一些研究比较了齐拉西酮和奥氮平这两种药物，但大多数被选为慢性患者的受试者。因此，本研究旨在比较齐拉西酮与奥氮平在未治疗的首发精神分裂症中的疗效和安全性。方法：将80例患者随机分配至6周治疗期，每天80-160 mg /天的齐拉西酮或10-20 mg /天的奥氮平。主要疗效指标为阳性和阴性综合征量表以及临床总体印象严重程度量表评分。第二项功效指标是治疗的反应率。还进行了耐受性评估。结果：79例患者完成了试验。齐拉西酮平均剂量为127.5 mg /天，奥氮平平均剂量为19.1 mg /天。在每个访视点，两组在主要或次要疗效测量中均未发现显着差异（所有p> 0.05）。奥氮平使体重显着增加，齐拉西酮组观察到更多锥体外系症状（所有p <0.05）。两种药物的耐受性良好，未观察到严重的不良事件。结论：齐帕西酮在短期治疗首发精神分裂症中的疗效与奥氮平相同，并且两种药物均具有良好的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号